Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs